In the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial, an abnormal DRE in conjunction with an elevated PSA more than doubled the likelihood of a positive biopsy (48.6% vs. 22.4%) [13]. The gene discussed is KLK3; the disease is Familial prostate cancer.